Ghassan K Abou-Alfa1, Marinela Capanu2, Eileen M O'Reilly3, Jennifer Ma4, Joanne F Chou2, Bolorsukh Gansukh4, Jinru Shia5, Marcia Kalin4, Seth Katz6, Leslie Abad7, Diane L Reidy-Lagunes3, David P Kelsen3, Helen X Chen8, Leonard B Saltz3. 1. Department of Internal Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States. Electronic address: abou-alg@mskcc.org. 2. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States. 3. Department of Internal Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States. 4. Department of Internal Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States. 5. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States. 6. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States. 7. Research Department, ImClone Systems, a wholly-owned subsidiary of Eli Lilly & Company, New York, NY, United States. 8. Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, United States.
Abstract
BACKGROUND & AIMS: IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study. METHODS: Patients with advanced HCC, Child-Pugh A-B8, received cixutumumab 6mg/kg weekly, in a Simon two-stage design study, with the primary endpoints being 4-month PFS and RECIST-defined response rate. Tissue and circulating markers plus different HCC scoring systems were evaluated for correlation with PFS and OS. RESULTS: As a result of pre-specified futility criteria, only stage 1 was accrued: N=24: median age 67.5 years (range 49-83), KPS 80% (70-90%), 20 males (83%), 9 stage III (37%)/15 stage IV (63%), 18 Child-Pugh A (75%), 11 HBV (46%)/10 HCV (42%)/11 alcoholic cirrhosis (46%)/2 NASH (8%), 11 (46%) diabetic. Median number of doses: 7 (range 1-140). Grade 3/4 toxicities >10% included: diabetes, elevated liver function tests, hyponatremia, and lymphopenia. Four-month PFS was 30% (95% CI 13-48), and there were no objective responses. Median overall survival was 8 months (95% CI 5.8-14). IGF-R1 staining did not correlate with outcome. Elevated IGFBP-1 correlated with improved PFS (1.2 [95% CI 1-1.4]; p 0.009) and OS (1.2 [95% CI 1.1-1.4]; p 0.003). CONCLUSIONS: Cixutumumab monotherapy did not have clinically meaningful activity in this unselected HCC population. Grade 3-4 hyperglycemia occurred in 46% of patients. Elevated IGFBP-1 correlated with improved PFS and OS.
BACKGROUND & AIMS:IGF-IR is implicated in hepatic carcinogenesis. This and preliminary evidence of biological activity of anti-IGF-1R monoclonal antibody cixutumumab in phase I trials prompted this phase II study. METHODS:Patients with advanced HCC, Child-Pugh A-B8, received cixutumumab 6mg/kg weekly, in a Simon two-stage design study, with the primary endpoints being 4-month PFS and RECIST-defined response rate. Tissue and circulating markers plus different HCC scoring systems were evaluated for correlation with PFS and OS. RESULTS: As a result of pre-specified futility criteria, only stage 1 was accrued: N=24: median age 67.5 years (range 49-83), KPS 80% (70-90%), 20 males (83%), 9 stage III (37%)/15 stage IV (63%), 18 Child-Pugh A (75%), 11 HBV (46%)/10 HCV (42%)/11 alcoholic cirrhosis (46%)/2 NASH (8%), 11 (46%) diabetic. Median number of doses: 7 (range 1-140). Grade 3/4 toxicities >10% included: diabetes, elevated liver function tests, hyponatremia, and lymphopenia. Four-month PFS was 30% (95% CI 13-48), and there were no objective responses. Median overall survival was 8 months (95% CI 5.8-14). IGF-R1 staining did not correlate with outcome. Elevated IGFBP-1 correlated with improved PFS (1.2 [95% CI 1-1.4]; p 0.009) and OS (1.2 [95% CI 1.1-1.4]; p 0.003). CONCLUSIONS:Cixutumumab monotherapy did not have clinically meaningful activity in this unselected HCC population. Grade 3-4 hyperglycemia occurred in 46% of patients. Elevated IGFBP-1 correlated with improved PFS and OS.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: May Daher; Mario E Lacouture; Dana Rathkopf; Robert G Maki; Mary Louise Keohan; Bolorsukh Gansukh; Helen Chen; Ghassan K Abou-Alfa Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: Jennifer D Wu; Austin Odman; Lily M Higgins; Kathy Haugk; Robert Vessella; Dale L Ludwig; Stephen R Plymate Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: Michael Höpfner; Alexander Huether; Andreas P Sutter; Viola Baradari; Detlef Schuppan; Hans Scherübl Journal: Biochem Pharmacol Date: 2006-03-10 Impact factor: 5.858
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Douglas Burtrum; Zhenping Zhu; Dan Lu; Donna Marie Anderson; Marie Prewett; Daniel S Pereira; Rajiv Bassi; Rashed Abdullah; Andrea T Hooper; Henry Koo; Xenia Jimenez; Danielle Johnson; Robin Apblett; Paul Kussie; Peter Bohlen; Larry Witte; Daniel J Hicklin; Dale L Ludwig Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang Journal: J Clin Oncol Date: 2014-12-29 Impact factor: 44.544
Authors: A Gualberto; M L Hixon; D D Karp; D Li; S Green; M Dolled-Filhart; L G Paz-Ares; S Novello; J Blakely; C J Langer; M N Pollak Journal: Br J Cancer Date: 2010-11-23 Impact factor: 7.640
Authors: Antonio M Lerario; Francis P Worden; Carole A Ramm; Elizabeth A Hesseltine; Elizabeth A Hasseltine; Walter M Stadler; Tobias Else; Manisha H Shah; Edem Agamah; Krishna Rao; Gary D Hammer Journal: Horm Cancer Date: 2014-05-22 Impact factor: 3.869
Authors: Anthony B El-Khoueiry; Robert O'Donnell; Thomas J Semrad; Philip Mack; Suzette Blanchard; Nathan Bahary; Yixing Jiang; Yun Yen; John Wright; Helen Chen; Heinz-Josef Lenz; David R Gandara Journal: Cancer Chemother Pharmacol Date: 2018-03-08 Impact factor: 3.333